Patents for A61P 33 - Antiparasitic agents (21,787) |
---|
10/04/2000 | CN1268948A Optically pure camptothecin analogues, optically pure synthessi intermdidate and method for preparing same |
10/03/2000 | US6127554 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents |
10/03/2000 | US6127543 Containing basic structural components of a molecule with antimalarial properties such as quinine, chloroquinine or mepacrine, as well as one or more ferrocene groups; increased therapeutic activity; bioavailability |
10/03/2000 | US6127398 An enzyme inhibitor for the inhibition of phosphodiesterase typeiv or the production of tumor necrosis factor in a mammal; treating asthma, arthritis, bronchitis, chronic obstructive airway disease, psoriasis, allergic rhinitis |
09/28/2000 | WO2000056919A1 Screening method involving mgdg synthase |
09/28/2000 | WO2000056891A2 Human transmembrane proteins |
09/28/2000 | WO2000056772A1 Human antibodies that bind human il-12 and methods for producing |
09/28/2000 | WO2000056767A1 46 human secreted proteins |
09/28/2000 | WO2000056763A1 A novel polypeptide and its derivatives, homologues and analogues |
09/28/2000 | WO2000056757A1 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone |
09/28/2000 | WO2000056755A1 49 human secreted proteins |
09/28/2000 | WO2000056751A1 50 human secreted proteins |
09/28/2000 | WO2000056346A1 Stable oil-in-glycerin emulsion |
09/28/2000 | WO2000056333A1 Combination of antibiotic and nucleic acid binding compound for bacterial antibiotic resistance |
09/28/2000 | WO2000023592A9 Minimal promoters and uses thereof |
09/28/2000 | WO2000022143A3 Protein kinase homologs |
09/28/2000 | CA2669512A1 Human antibodies that bind human il-12 and methods for producing |
09/28/2000 | CA2371987A1 Screening method involving mgdg synthase |
09/28/2000 | CA2368210A1 50 human secreted proteins |
09/28/2000 | CA2365247A1 49 human secreted proteins |
09/28/2000 | CA2365243A1 Human transmembrane proteins |
09/28/2000 | CA2365223A1 46 human secreted proteins |
09/28/2000 | CA2365081A1 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone |
09/27/2000 | EP1038000A1 Compounds and methods for the detection and prevention of (t. cruzi) infection |
09/27/2000 | EP1037609A1 Aqueous insecticidal pour-on formulation |
09/27/2000 | CN1268140A Monocyclic L-nucleosides, analogs and uses thereof |
09/27/2000 | CN1268125A Dicyclanil Polymorphs and hydrates and their preparation |
09/27/2000 | CN1056883C Process for producing avermectins B and cultures therefor |
09/21/2000 | WO2000055332A2 Human regulators of intracellular phosphorylation |
09/21/2000 | WO2000055126A2 N-cyanomethylamides as protease inhibitors |
09/21/2000 | WO2000055125A2 N-cyanomethyl amides as protease inhibitors |
09/21/2000 | WO2000054789A1 Bacterial membrane fractions with adjuvant effect |
09/21/2000 | WO2000054766A1 Agents and methods for promoting production gains in animals |
09/21/2000 | WO2000012508A3 Pyrrolbenzodiazepines |
09/21/2000 | CA2368148A1 Novel compounds and compositions as protease inhibitors |
09/21/2000 | CA2368122A1 Novel compounds and compositions as protease inhibitors |
09/21/2000 | CA2367917A1 Bacterial membrane fractions with adjuvant effect |
09/21/2000 | CA2367444A1 Agents and methods for promoting production gains in animals |
09/21/2000 | CA2364739A1 Regulators of intracellular phosphorylation |
09/20/2000 | EP1035835A1 Long acting injectable formulations containing hydrogenated castor oil |
09/20/2000 | CN1056531C Chinese medicine composition for treating skin disease |
09/19/2000 | US6121431 Nucleoside derivatives |
09/19/2000 | US6120785 Antimycotic ectoparasiticidal product-external use |
09/19/2000 | US6120770 Isolated polypeptide |
09/14/2000 | WO2000053607A1 Camptothecin derivatives having antitumor activity |
09/14/2000 | WO2000053220A1 Lipoglycan compositions and methods of treating parasitic infections |
09/14/2000 | WO2000035430A3 Homer a new target of treating psychiatric disorders |
09/14/2000 | WO2000031263A3 Gtpase associated proteins |
09/14/2000 | WO2000025812A3 Method for preparing solid phase conjugate vaccines |
09/14/2000 | CA2364507A1 Lipoglycan compositions and methods of treating parasitic infections |
09/13/2000 | EP1034794A1 A formulation of dihydroartemisinin for the control of wide spectrum of malaria |
09/13/2000 | EP1033982A1 Agents for combating neospora spec |
09/13/2000 | CN1266459A Method and reagents for vaccination which generate a CD8 T cell immune response |
09/13/2000 | CN1266437A Improved process for antiparasitic agent |
09/13/2000 | CN1266423A 1-amino-alkylcyclohexane NMDA receptor antagonists |
09/12/2000 | US6117894 Maintains its stability after six months or more of storage. |
09/08/2000 | WO2000052056A2 Anti-plasmodium compositions and methods of use |
09/08/2000 | WO2000052005A1 Febrifugine and isofebrifugine and processes for the preparation of both |
09/08/2000 | WO2000051634A1 Vaccine preparations containing fatty acids as constituent |
09/08/2000 | WO2000023592B1 Minimal promoters and uses thereof |
09/08/2000 | WO2000019883A3 Compositions and methods of disease diagnosis and therapy |
09/08/2000 | CA2362477A1 Anti-plasmodium compositions and methods of use |
09/06/2000 | EP1032416A1 Neospora vaccines |
09/06/2000 | CN1265647A Acrylic metalloprotease inhibitor |
09/06/2000 | CN1056060C Medical ointment for treating scabies |
09/05/2000 | US6114393 Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa |
08/31/2000 | WO2000050562A2 Dna encoding snorf25 receptor |
08/31/2000 | WO2000050431A1 Platinum (ii) compounds |
08/31/2000 | WO2000050427A1 Optically pure camptothecin analogues |
08/31/2000 | WO2000050404A1 4-aminoquinolines as antimalarials |
08/31/2000 | WO2000050072A2 Method for the purification, recovery, and sporulation of cysts and oocysts |
08/31/2000 | WO2000050009A1 Methods for administering pharmacologically active compounds to vertebrates |
08/31/2000 | WO2000012507A3 Pyrrolobenzodiazepines |
08/31/2000 | CA2710788A1 Method for the purification, recovery, and sporulation of cysts and oocysts |
08/31/2000 | CA2364712A1 Platinum (ii) compounds |
08/31/2000 | CA2362906A1 Dna encoding snorf25 receptor |
08/30/2000 | EP1031351A1 Leishmaniasis remedy containing glucopyranose derivative as the active ingredient |
08/30/2000 | EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers |
08/30/2000 | EP1030653A1 Dinitroaniline liposomal formulations and processes for their preparation |
08/30/2000 | EP0787141B1 Cyclic depsipeptide sulfonylation, sulfenylation and phosphorylation process |
08/30/2000 | CN1265149A Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
08/30/2000 | CN1265113A Prodn. method of avermectin compounds |
08/30/2000 | CN1265038A Cellular vesicle called 'exosome', prepn. and use thereof in immune stimulation |
08/29/2000 | US6110958 Pyrrole compounds having parasiticidal properties |
08/29/2000 | US6110928 Human or veterinary medicine |
08/29/2000 | CA2018704C N-phenylpyrazole derivatives |
08/29/2000 | CA2012081C 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi 2 derivatives |
08/24/2000 | WO2000049146A1 Malaria vaccine |
08/24/2000 | WO2000048630A1 Immunogenic complexes and methods relating thereto |
08/24/2000 | WO2000048629A1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS |
08/24/2000 | WO2000048628A1 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response |
08/24/2000 | WO2000048615A2 TREATMENT OF CHRONIC VIRAL INFECTIONS WITH $i(M. VACCAE) |
08/24/2000 | WO2000048610A1 Chemical compounds |
08/24/2000 | WO2000048609A1 Chemical compounds |
08/24/2000 | WO2000048558A1 Modified calycins |
08/24/2000 | CA2372059A1 Use of an ompa enterobacterium protein associated with the elagigiltv peptide for treating melanomas |
08/24/2000 | CA2363670A1 Chemical compounds |
08/24/2000 | CA2362306A1 Chemical compounds |
08/24/2000 | CA2362284A1 Modified calycins |
08/24/2000 | CA2362192A1 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response |